Chemo-Free hope: new antibody tackles rare lymphoma

NCT ID NCT03322865

Ongoing Disease control Sponsor: Christian Buske Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests obinutuzumab, a targeted antibody, in 56 people with newly diagnosed marginal zone lymphoma who need treatment but cannot have or have failed local therapy. The goal is to see if this drug can shrink tumors without the side effects of chemotherapy. Participants receive the drug intravenously for six months, then maintenance doses if they respond.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Obinutuzumab (GA101)
What this could lead to: If successful, this could offer a chemotherapy-free treatment option for marginal zone lymphoma that is more effective than rituximab alone.
What could go wrong: This is a small, early-phase trial (56 participants) with no comparison group, so results may not confirm superiority. The drug may cause infusion reactions or not prevent relapse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MARGINAL ZONE LYMPHOMA

Contacts and locations

Locations

Augusta-Kranken-Anstalt gGmbH

Bochum, 44791, Germany
Gemeinschaftspraxis für Hämatologie und Onkologie

Münster, 48149, Germany
Institut für Versorgungsforschung GbR

Koblenz, 56068, Germany
Klinikum Passau

Passau, 94032, Germany
University Hospital Essen

Essen, 45147, Germany
University Hospital Halle

Halle, 06120, Germany
University Hospital Mainz

Mainz, 55101, Germany
University Hospital Münster

Münster, 48149, Germany
University Hospital Ulm

Ulm, 89081, Germany
Universitätsklinikum Freiburg

Freiburg im Breisgau, 79106, Germany
Universitätsklinikum Mannheim

Mannheim, 68167, Germany
Universitätsmedizin Georg-August-University

Göttingen, 37075, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.